|
|
|
|
Kewaunee Scientific Corporation (NASDAQ: KEQU) |
|
|
|
| |
Kewaunee Scientific's Working Capital Ratio
KEQU's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth
In the wake of the increase in Current Liabilities in the third quarter 2024, Working Capital Ratio fell to 2.16 below Kewaunee Scientific Corporation average.
Within Laboratory Analytical Instruments industry 11 other companies have achieved higher Working Capital Ratio than Kewaunee Scientific in third quarter 2024. While Working Capital Ratio total ranking has improved so far during the Q3 2024 to 1362, from total ranking in the second quarter 2024 at 1556.
Explain Working Capital Ratio
How much Current Assetss KEQU´s has?
What are KEQU´s Current Liabilities?
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| KEQU Working Capital Ratio |
(Jan 31 2025)
Q3 |
(Oct 31 2024)
Q2 |
(Jul 31 2024)
Q1 |
(Apr 30 2024)
Q4 |
(Jan 31 2024)
Q3 |
| Y / Y Current Liabilities Change |
19.05 % |
-5.84 % |
-17.05 % |
1.82 % |
-4.68 % |
| Y / Y Current Assets Change |
12.95 % |
6.12 % |
-0.88 % |
10.12 % |
5.02 % |
| Working Capital Ratio MRQ |
2.16 |
2.64 |
2.53 |
2.37 |
2.28 |
| KEQU's Total
Ranking |
# 1362 |
# 1556 |
# 1650 |
# 1356 |
# 1042 |
| Seq. Current Liabilities Change |
37.56 % |
-0.59 % |
-10.04 % |
-3.23 % |
8.8 % |
| Seq. Current Assets Change |
12.63 % |
4.03 % |
-4.25 % |
0.69 % |
5.81 % |
| Working Capital Ratio third quarter 2024 Company Ranking |
| Within: |
No. |
| Laboratory Analytical Instruments Industry |
# 12 |
| Healthcare Sector |
# 400 |
| Overall Market |
# 1362 |
| Working Capital Ratio Statistics |
| High |
Average |
Low |
| 2.68 |
2.22 |
1.45 |
| (Apr 30 2014) |
|
(Jan 31 2022) |
Cumulative Kewaunee Scientific's Working Capital Ratio
KEQU's Working Capital Ratio for the trailling 12 Months
KEQU Working Capital Ratio |
(Jan 31 2025)
12 Months |
(Oct 31 2024)
12 Months |
(Jul 31 2024)
12 Months |
(Apr 30 2024)
12 Months |
(Jan 31 2024)
12 Months |
| Y / Y Current Liabilities TTM Growth |
-0.63 % |
-6.67 % |
-7.59 % |
-6.09 % |
-7.67 % |
| Y / Y Current Assets TTM Growth |
7.08 % |
5.01 % |
3.56 % |
2.58 % |
-0.82 % |
| Working Capital Ratio TTM |
2.4 |
2.45 |
2.38 |
2.27 |
2.23 |
| Total Ranking TTM |
# 2408
| # 3520
| # 3696
| # 1028
| # 2120
|
| Seq. Current Liabilities TTM Growth |
5.14 % |
-1.43 % |
-4.55 % |
0.44 % |
-1.24 % |
| Seq. Current Assets TTM Growth |
3.26 % |
1.48 % |
-0.22 % |
2.41 % |
1.26 % |
On the trailing twelve months basis Due to growth in Current Liabilities in the Q3 2024 to $50.17 millions, cumulative Working Capital Ratio decreased to 2.4 above the KEQU average Working Capital Ratio. Working Capital Ratio is the average cumulative value over the last four quarters.
Among companies operating within Laboratory Analytical Instruments industry 15 other companies have achieved higher Working Capital Ratio than Kewaunee Scientific. While Working Capital Ratio overall ranking has improved so far to 2408, from total ranking during the twelve months ending second quarter 2024 at 3520.
Explain Working Capital Ratio
How much Current Assetss KEQU´s has?
What are KEQU´s Current Liabilities?
| TTM Working Capital Ratio Company Ranking |
| Within: |
No. |
| Within the Laboratory Analytical Instruments Industry |
# 16 |
| Healthcare Sector |
# 533 |
| Within the Market |
# 2408 |
| trailing twelve months Working Capital Ratio Statistics |
| High |
Average |
Low |
| 2.53 |
2.21 |
1.6 |
| (Dec. 30, 2014) |
|
(Jan 31 2022) |
| Companies with similar Working Capital Ratio in the quarter ending Jan 31 2025, within Laboratory Analytical Instruments Industry | Working Capital Ratio | Jan 31 2025 MRQ Current Assets | Jan 31 2025 MRQ Current Liabilities | | Cytek Biosciences Inc | 5.86 | $ 396.446 Millions | $ 67.663 Millions | | Standard Biotools Inc | 5.70 | $ 375.880 Millions | $ 65.894 Millions | | 10x Genomics Inc | 4.97 | $ 584.387 Millions | $ 117.633 Millions | | Scientific Industries Inc | 4.74 | $ 8.288 Millions | $ 1.747 Millions | | Rapid Micro Biosystems Inc | 4.61 | $ 80.917 Millions | $ 17.565 Millions | | Revvity Inc | 3.60 | $ 2,349.608 Millions | $ 653.100 Millions | | Akoya Biosciences Inc | 2.61 | $ 76.732 Millions | $ 29.444 Millions | | Agilent Technologies inc | 2.20 | $ 4,107.000 Millions | $ 1,869.000 Millions | | Kewaunee Scientific Corporation | 2.16 | $ 108.612 Millions | $ 50.171 Millions | | Waters Corporation | 2.11 | $ 1,669.111 Millions | $ 789.758 Millions | | Illumina Inc | 1.78 | $ 2,746.000 Millions | $ 1,547.000 Millions | | Bruker Corporation | 1.60 | $ 2,053.200 Millions | $ 1,281.300 Millions | | Avantor Inc | 1.07 | $ 2,146.600 Millions | $ 2,007.500 Millions | | Bionano Genomics Inc | 1.06 | $ 39.489 Millions | $ 37.344 Millions | | Mettler toledo International Inc | 1.02 | $ 1,193.906 Millions | $ 1,168.193 Millions | | Precipio inc | 0.93 | $ 3.451 Millions | $ 3.714 Millions | | Harvard Bioscience Inc | 0.88 | $ 45.117 Millions | $ 51.152 Millions | | Accelerate Diagnostics Inc | 0.71 | $ 22.238 Millions | $ 31.201 Millions |
|
Date modified: 2025-03-16T18:30:23+00:00
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
